Centocor Remicade Black Box MD Visits Will Be 85% Complete By Aug. 31

Centocor sales representatives will visit 85% of targeted Remicade prescribers by the end of August to inform them of a new black box warning added to labeling for the rheumatoid arthritis therapy, Exec Director-Medical Affairs Tom Schaible, PhD, told the FDA Arthritis Advisory Committee.